Testing sotorasib for untreated lung cancer with KRAS G12C mutation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that has spread or come back.
- You have a specific genetic change in your cancer called KRAS G12C, found on a biopsy or blood test.
- You have not received any previous treatment for your advanced lung cancer.
- You are willing to have two tumor biopsies (tissue samples) – one before starting the drug and one during treatment.
- You are 18 or older and your overall health status is good (able to do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
This study tests a drug called sotorasib in people with brain tumors who are already scheduled for surgery or a biopsy. It may help find out if the drug can reach and treat the tumor.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This Phase 2 study tests sotorasib (also called AMG510) in people with Stage III lung cancer that cannot be removed by surgery and that has a specific KRAS mutation (p.G12C). You may be able to join if you cannot safely receive chemo-radiotherapy at the same time, and the study checks whether sotorasib can help shrink or control the cancer.
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
Hear when a new Non-small Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.